GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GlaxoSmithKline Pharmaceuticals reported a 12.5% rise in quarterly profit on Thursday as the Indian unit of UK's GSK plc saw strong demand for its vaccines and general medicine.

GSK's India unit posts Q2 profit rise on strong vaccine demand

GSK NYSE: GSK is not immune to the patent cliff faced by the pharmaceutical industry, but it is about as well prepared as it can be. The company faces a smaller impact than others, has years to go before the impact is felt, and is well on track to grow now and replace the lost revenue when patent expiry comes.

GSK is a remedy for the winter investment blahs

DexCom

Tenet Healthcare

A record number of Americans are now turning 65, Forbes recently reported, amid tens of millions of Baby Boomers. In fact, according to one report, 76.4 million Baby Boomers are living in America currently.

3 Healthcare Stocks Getting Help From the Aging Population

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?

GSK PLC (LSE:GSK, NYSE:GSK)'s seemingly positive earnings release on Wednesday has been labelled as just that by Stifel analysts, who were left mulling reasons for a subsequent drop in its share price. Though GSK lifted its full-year guidance following strong third-quarter trading, Wednesday's update actually prompted a 2% slide in the pharmaceuticals giant's shares.

GSK falls victim of ‘hard to please' pharma market

Caterpillar

For conservative investors, including those in and nearing retirement, highly reliable dividend stocks with a growth component are an excellent tool. That's because these equities produce regular income and are likely to generate significant returns for investors through increases in their stock prices.

3 Top Dividend Stock Picks for Steady Income and Capital Appreciation

GSK plc (NYSE:GSK ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Nick Stone - Head of Investor Relations Emma Walmsley - Chief Executive Officer Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare Julie Brown - Chief Financial Officer Conference Call Participants Graham Parry - Bank of America Kerry Holford - Berenberg Simon Baker - Redburn Andrew Baum - Citi Richard Parkes - BNP Paribas James Gordon - JPMorgan Mark Purcell - Morgan Stanley Steve Scala - TD Cowen Peter Welford - Jefferies Emily Field - Barclay Nick Stone Hello, everyone. It's Nick Stone, Head of Investor Relations.

GSK plc (GSK) Q3 2023 Earnings Call Transcript

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.

GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance

GSK PLC (LSE:GSK, NYSE:GSK) has received mixed reactions from City analysts despite an objectively strong third-quarter performance and raised financial guidance. Shore Capital Markets praise the “stellar debut” of respiratory syncytial virus vaccine Arexvy, which helped to drive up vaccine sales 13% over targets.

GSK receives a mixed City reaction despite raised outlook

GSK raised its outlook for the second time this year on the back of a strong launch for its RSV vaccine. But GSK stock fell.

GSK Hikes Guidance On The Back Of Its Strong RSV Vaccine Launch

GSK (GSK) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.09 per share a year ago.

GSK (GSK) Q3 Earnings and Revenues Surpass Estimates

High demand for the vaccine pulled in around $850 million during the third quarter—reportedly double what analysts were expecting—and GSK said annual sales could top $1 billion.

GSK Boosts Profit Forecasts After ‘Outstanding' RSV Vaccine Launch

GSK PLC (LSE:GSK, NYSE:GSK) said a strong third quarter performance has driven a further upgrade to full-year guidance boosted by demand for its respiratory treatment in the US. The pharmaceuticals company expects full-year turnover to increase by 12% to 13%, up from 8% to 10% before, with adjusted operating profit growth between 13% to 15%, up from 11% to 13% previously.

GSK raises outlook amid strong demand for new RSV vaccine

GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncytial virus (RSV) vaccine and steady demand for its shingles shot.

GSK raises annual forecasts again on strong Arexvy launch

The company will for the first time report sales of Arexvy, its new RSV vaccine that launched this fall.

GSK Reports Earnings Wednesday. What to Watch.

Johnson & Johnson

British drugmaker GSK said on Tuesday it had signed a $1 billion agreement with Johnson & Johnson-owned Janssen for exclusive rights to further develop and commercialize the U.S.-based company's hepatitis B therapy.

GSK signs $1 bln deal for exclusive license to J&J's hepatitis B therapy

Pfizer

Pfizer , which dominated COVID vaccine sales, now finds itself looking up at GSK , whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer.

Pfizer RSV vaccine lags GSK's as head-to-head competition underway

British drugmaker GSK said on Monday its cancer drug Jemperli met the primary goal of overall survival in patients with primary advanced or recurrent endometrial cancer in a late-stage trial.

GSK says endometrial cancer drug meets primary goal in late-stage trial

Bionano Genomics

One of the New York Yankees' most well-known players', Yogi Berra, famous for his strange, yet funny statements, used to say, “This is deja vu all over again.” That's how I feel about U.S. stocks at this point.

3 Deeply Undervalued Growth Stocks

Strong sales of its shingles vaccine Shingrix has already seen GSK upgrade its forecasts for  2023. The pharmaceutical giant now expects turnover to increase by 8-10%, up from the previous estimate of 6-8%, and adjusted operating profit growth of 11-13%, up from 10-12%.

GSK shingles vaccine to underpin third quarter update

Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Expected to Beat Earnings Estimates: Should You Buy?

The results suggest that GSK's shot could help protect a wider population from RSV, which causes thousands of hospitalizations and deaths each year.

RSV vaccine from GSK shows potential to protect adults 50 to 59

PHILADELPHIA--(BUSINESS WIRE)-- #AREXVY--New data for AREXVY, GSK's RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease.

New Data for AREXVY, GSK's RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease

GSK said they plan to submit data to regulators as soon as possible and expect a decision in 2024 on whether the shot, already approved for older adults, can be marketed towards people ages 50 to 59.

RSV Vaccine Shows Hopeful Early Results In 50 To 59-Year-Olds, GSK Says

GSK PLC (LSE:GSK, NYSE:GSK) today unveiled ‘positive' preliminary results from the third phase of its trial of Arexvy, a vaccine against the potentially fatal respiratory syncytial virus (RSV) that causes lower respiratory tract disease.   Tony Wood, chief scientific officer at GSK, said: "This trial reinforces our confidence in our RSV vaccine's ability to help protect adults aged 50 to 59 at increased risk for RSV-LRTD.

News for GlaxoSmithKline Stock (GSK)